M2Bio Sciences, Inc.

M2Bio Sciences, Inc.

Alternative Medicine

At the forefront of medicinal cannabis and mushrooms - Trading on the OTC: $MRES

About us

M2Bio Sciences, Inc. is a nutraceutical biotechnology company that researches, develops and commercialises a range of CBD-based products under the Dr. AnnaRx™, Medspresso™ and Liviana™ brands. In addition, its new wholly-owned division, is researching and developing indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer's and Parkinson's. Our vision is to improve people’s quality of life by unleashing the full potential of medicinal cannabis and mushrooms. Our mission is to advance botanical-based medicine to the forefront. From seed to shelf and spore to store, we are driven by a passion for medicine and science. We live by the values of: Quality. Excellence. Science. Traceability. Accountability. Humility. M2Bio is listed and traded on the Over The Counter Bulletin Board of NASDAQ under the trading symbol “$MRES”. The global market for legal cannabis is according to Euromonitor International anticipated to grow 1,283 percent in value of sales, in the next seven years, from US$12B to US$166B at a CAGR of 45.5 percent (2018-2025), subject to increased legalisation.

Website
https://m2bio.co
Industry
Alternative Medicine
Company size
11-50 employees
Headquarters
Cape Town
Type
Public Company
Founded
2018
Specialties
Cannabis, Cannabidiol, Medicine, Biotechnology, Psilocybin, Medicinal Mushrooms, Health , Neuroscience, and Alternative Medicine

Locations

Employees at M2Bio Sciences, Inc.

Updates

Similar pages

Browse jobs

Funding

M2Bio Sciences, Inc. 1 total round

Last Round

Post IPO equity

US$ 450.0K

See more info on crunchbase